Program areas at ASCO
See schedule o:scientific & medical education:asco's meeting portfolio delivers to Asco's core audience of health professionals, the science and education critical to improving patient care and Clinical practice by hosting conferences that bring together faculty and practitioners both in-person and online. In 2023, Asco's premier annual meeting, through over 220 sessions, reached an audience of 36,750 professionals, including over 14,000 professionals from 140 non-us countries, both in-person and online. Through Asco's additional meetings, the Asco gastrointestinal cancers symposium, the Asco genitourinary cancers symposium, the Asco quality care symposium, Asco breakthrough, and the best of Asco annual meeting, a further 11,325 professionals, over 4,600 of whom were outside the united states, benefited from the education, science, and networking that Asco provided.
See schedule o:research initiatives - tapur/centra:asco's center for research and analytics leads Asco's research efforts, including its Clinical cancer research programs. Major programs and projects include: (1) the targeted agent and profiling utilization registry which is precision medicine basket trial investigating the efficacy of more than 15 different anti-cancer targeted agents in patients with advanced cancers and has enrolled almost than 3,000 patients since it opened in 2016 and continues to publish trial results in peer-reviewed Clinical cancer research journals and present results at Clinical cancer research conferences; (2) Asco's covid-19 registry which includes a database of over 6,000 patients with cancer and covid-19 from 2020 to 2022 and research on the database by centra staff and made available to external researchers (the registry closed to data collection at the end of 2023 although data is still available for use); (3) Asco's member research survey pool, which facilitates research of cancer care providers by disseminating surveys from meritorious survey research projects to Asco members who have agreed to be a part of the survey pool; (4) the state of cancer care in america program, which assesses and reports on and report on the state of and changes in cancer care in the us; (5) Asco's work in improving access to Clinical trials through training for sites and working to combat barriers to enrollment for under-represented populations of patients; and (6) the start-up for a new Clinical research study, the cdk4/6 inhibitor dosing study, which will open to enrollment in 2024 and evaluates standard vs. titrated dosing approaches for patients age 65 and older with hr+/her2- metastatic breast cancer. Centra also supports workshops, meetings, and research projects with other stakeholders in cancer research, including the nci, the fda's Oncology center for excellence, and other non-profit groups, such as the friends of cancer research.
See schedule o:quality of care initiatives - cancerlinq, quality measures, guidelines and qopi:quality Oncology practice initiative (qopi). A quality self assessment and improvement program for outpatient medical Oncology and hematology-oncology practices: qopi provides a web-based data collection tool that allows practices to 1) report on various cancer care quality measures, 2) receive analyzed data on practice performance, and 3) compare performance against their peers for data-driven improvement activities. Practices participate annually and over 263 pratices particapted in 2023.quality training program. Asco's quality training program is designed to educate and train hematolgy-onocology practice teams, the techniques of Clinical care and operational performance quality improvement. Recent particpants have included, by intentional recruitment, practices serving urban and rural underserved populations adressing health disparity. 290 Oncology professionals received training in 2023.guidelines:a critical component of the Society's quality efforts, the Asco guidelines program actively engages with more than 1,000 Asco member volunteers, on a yearly basis, to develop evidence and expert-driven recommendations that inform high-quality and equitable cancer care worldwide. Asco's guidelines program which includes traditional as well as living Clinical practice guidelines, updates, and organizational standards, focuses on content areas with identified knowledge gaps, high uncertainty, or unmet and pressing Clinical needs facing Oncology care teams in Clinical practice. Asco's guidelines resources are designed to promote guideline-concordant cancer care at the clinician, caregiver, and patient level. For patients and caregivers, complex guideline information is distilled and presented in a user-friendly format through Asco's cancer.net. For clinicians, these tools are offered through concise practice-facing companion articles, summary recommendation tables, algorithms, podcasts, visual abstracts, and other resources that are accessible through Asco journals, the Asco website, and the Asco guidelines app.published as a regular, and often most read, feature in the journal of Clinical Oncology (jco) with over 1.3 million downloads in 2023, guidelines also serve as the evidence foundation for Asco's member education, patient education, policy, care delivery, and quality efforts, all with the goal of cancer treatment and care informed by the highest quality evidence and expert interpretation, integrated into global practice at the point of patient care. Asco typically engages 30-40 guideline expert panels at any given time and publishes between 20-25 new or updated guidelines each year; with a growing library of guideline summaries that have been translated into spanish. Twenty-three guideline products were published in the jco in 2023, including several rapid updates and multiple iterations of Asco's comprehensive living guideline addressing the care of patients with metastatic non-small cell lung cancer. In addition, 13 companion articles providing guideline Clinical insights were published in the jco Oncology practice.
Examples of other programs:scientific publications: Asco produces a number of professional publications and general publications focused on Clinical Oncology. Asco publishes high-quality, peer-reviewed scientific papers in its journals: - journal of Clinical Oncology (jco)- jco global Oncology (jco go)- jco Clinical cancer informatics (jco cci)- jco precision Oncology (jco po)- jco Oncology practice (jco op)- Asco daily newsasco also provides content and distribution lists for trade publications. While not owned or published by Asco, the publications cover news and information of interest to the professional Oncology community.center for global impact:asco's international affairs department has transitioned to the center for global impact (cgi). Cgi partners across Asco and Oncology communities worldwide to integrate global perspectives into Asco strategies and operations, and to catalyze and advance Asco's global impact goals as directed by the Society's mission, vision, and strategic plans. Cgi serves as a resource across Asco for global issues relevant to Asco, with a particular emphasis on volunteer engagement, diplomacy, strategic planning, program delivery, and global operations. It does this through the following:joint sessions (international cancer conferences)the international cancer corps' (icc)the international development and education award (idea)